DRUG ADDICTION

Pharmacology and Therapeutics: Principles to Practice

Volumn , Issue , 2008, Pages 817-835

  Choi, Doo Sup ^a   Karpyak, Victor M ^a   Frye, Mark A ^a   Hall Flavin, Daniel K ^a   Mrazek, David A ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551537633     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3291-5.50059-7     Document Type: Chapter

References (145)

1. American Psychiatric Association (2004) Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Washington, DC: American Psychiatric Press
2. P Pouletty (2002) Drug addictions: towards socially accepted and medically treatable diseases. Nat Rev Drug Discov 1 731-736.
3. GF Koob and M Le Moal (2006) Neurobiology of Addiction San Diego: Elsevier
4. EJ Nestler (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8 1445-1449.
5. United Nations International Drug Control Programme and World Health Organization Informal Expert Committee on the Craving Mechanism (1992) Technical Report Series No V. Geneva: World Health Organization
6. MJ Kreek, DA Nielsen, ER Butelman and KS LaForge (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8 1450-1457.
7. C Johnson, T Drgon, QR Liu, et al. (2006) Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet 141 844-853.
8. R Weinshilboum and L Wang (2004) Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3 739-748.
9. SL Boehm 2nd, I Ponomarev, AW Jennings, et al. (2004) γ-Aminobutyric acid A receptor subunit mutant mice: new perspectives on alcohol actions. Biochem Pharmacol 68 1581-1602.
10. JH Krystal, IL Petrakis, G Mason, et al. (2003) N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 99 79-94.
11. A Mansour, H Khachaturian, ME Lewis, et al. (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11 308-314.
12. H Rang, MM Dale, JM Ritter and PK Moore (2003) Pharmacology 5th ed. Edinburgh: Churchill Livingstone
13. JH Meyer and LH Quenzer (2005) Psychopharmacology: Drugs, The Brain, and Behavior Sunderland, MA: Sinauer Associates
14. M Cordero-Erausquin, LM Marubio, R Klink and JP Changeux (2000) Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci 21 211-217.
15. MH Cobb, TG Boulton and DJ Robbins (1991) Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 2 965-978.
16. MR Picciotto, M Zoli, V Zachariou and JP Changeux (1997) Contribution of nicotinic acetylcholine receptors containing the beta 2-subunit to the behavioural effects of nicotine. Biochem Soc Trans 25 824-829.
17. VI Pidoplichko, M DeBiasi, JT Williams and JA Dani (1997) Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390 401-404.
18. J Foulds, JA Stapleton, N Bell, et al. (1997) Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. Drug Alcohol Depend 44 105-115.
19. BE Hildebrand, G Panagis, TH Svensson and GG Nomikos (1999) Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21 560-574.
20. RT Jones (1990) The pharmacology of cocaine smoking in humans. NIDA Res Monogr 99 30-41.
21. I Sora, FS Hall, AM Andrews, et al. (2001) Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A 98 5300-5305.
22. GR Uhl, FS Hall and I Sora (2002) Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 7 21-26.
23. ND Volkow, GJ Wang, JS Fowler, et al. (1999) Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of “high.”. J Pharmacol Exp Ther 288 14-20.
24. ND Volkow, GJ Wang, JS Fowler, et al. (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155 1325-1331.
25. UD McCann and GA Ricaurte (2004) Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27 821-826.
26. G Hatzidimitriou, UD McCann and GA Ricaurte (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19 5096-5107.
27. S Agurell, M Halldin, JE Lindgren, et al. (1986) Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 21-43.
28. WA Devane, FA Dysarz 3rd, MR Johnson, et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 605-613.
29. LA Matsuda, SJ Lolait, MJ Brownstein, et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 561-564.
30. L Iversen (2003) Cannabis and the brain. Brain 126(Pt 6), 1252-1270.
31. A Calignano, G La Rana, A Giuffrida and D Piomelli (1998) Control of pain initiation by endogenous cannabinoids. Nature 394 277-281.
32. JD Richardson, L Aanonsen and KM Hargreaves (1998) Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 18 451-457.
33. SC Black (2004) Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5 389-394.
34. G Marsicano, CT Wotjak, SC Azad, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 530-534.
35. G Tanda, FE Pontieri and G Di Chiara (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276 2048-2050.
36. M Haney, A Bisaga and RW Foltin (2003) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 166 77-85.
37. S Ghozland, HW Matthes, F Simonin, et al. (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22 1146-1154.
38. EM Kouri and HG Pope Jr (2000) Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 8 483-492.
39. D Goldman, G Oroszi and F Ducci (2005) The genetics of addictions: uncovering the genes. Nat Rev Genet 6 521-532.
40. MA Schuckit and TL Smith (2006) The relationship of behavioural undercontrol to alcoholism in higher-functioning adults. Drug Alcohol Rev 25 393-402.
41. SE Luczak, SH Shea, AC Hsueh, et al. (2006) ALDH22 is associated with a decreased likelihood of alcohol-induced blackouts in Asian American college students. J Stud Alcohol 67 349-353.
42. JA Edwards and J Price (1967) Metronidazole and human alcohol dehydrogenase. Nature 214 190-191.
43. JL Mottin (1973) Drug-induced attenuation of alcohol consumption: a review and evaluation of claimed, potential or current therapies. Q J Stud Alcohol 34 444-472.
44. CW Wilson, C O'Brien and JG MacAirt (1973) The effect of metronidazole on the human taste threshold to alcohol. Br J Addict Alcohol Other Drugs 68 99-110.
45. HN Bhargava, GA Matwyshyn, PM Gerk, et al. (1994) Effects of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat. Gen Pharmacol 25 149-155.
46. JH Mendelson, J Ellingboe, JC Kuehnle and NK Mello (1980) Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity. J Pharmacol Exp Ther 214 503-506.
47. HD Kleber, TR Kosten, J Gaspari and M Topazian (1985) Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 20 66-72.
48. JR Volpicelli, AI Alterman, M Hayashida and CP O'Brien (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 876-880.
49. JR Volpicelli, MA Davis and JE Olgin (1986) Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci 38 841-847.
50. SS O'Malley, AJ Jaffe, G Chang, et al. (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49 881-887.
51. I Yano and AE Takemori (1977) Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. Res Commun Chem Pathol Pharmacol 16 721-734.
52. M Berglund (2005) A better widget? Three lessons for improving addiction treatment from a meta-analytical study. Addiction 100 742-750.
53. NS Miller and MS Gold (1998) Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence. Am Fam Physician 58 139-146.
54. EM Jellinek (1952) Phases of alcohol addiction. Q J Stud Alcohol 13 673-684.
55. CP O'Brien (2005) Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162 1423-1431.
56. R Verheul, W van den Brink and P Geerlings (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34 197-222.
57. W Ooteman, M Koeter, R Verheul, et al. (2006) Development and validation of the Amsterdam Motives for Drinking Scale (AMDS): an attempt to distinguish relief and reward drinkers. Alcohol Alcohol 41 284-292.
58. National Institute of Drug Abuse (1999) Principles of Drug Addiction Treatment Bethesda, MD: National Institutes of Health
59. M Bergland, S Thelander and E Jonsson (Eds) (2003) Treating Alcohol and Drug Abuse: An Evidence Based Review Weinheim, Germany: Wiley
60. MJ Kreek, KS LaForge and E Butelman (2002) Pharmacotherapy of addictions. Nat Rev Drug Discov 1 710-726.
61. AJ Roberts, JS McDonald, CJ Heyser, et al. (2000) mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 293 1002-1008.
62. C Bouza, M Angeles, A Munoz and JM Amate (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99 811-828.
63. A Dahchour and P De Witte (2000) Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 60 343-362.
64. COMBINE Study Research Group (2003) Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res 27 1123-1131.
65. P De Witte, E Pinto, M Ansseau and P Verbanck (2003) Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 27 189-197.
66. R Spanagel, G Pendyala, C Abarca, et al. (2005) The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 11 35-42.
67. MJ Kreek and FJ Vocci (2002) History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 23 93-105.
68. AM Davis and CE Inturrisi (1999) d-Methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 289 1048-1053.
69. TP George and SS O'Malley (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25 42-48.
70. Work Group on Substance Use Disorders (Kleber HD WR, Anton RF, etal); Steering Committee on Practice Guidelines, American Psychiatric Association (McIntyre JS, Charles SC, Anzia DJ, etal). Clinical practice guidelines: Treatment of patients with substance use disorders, second edition. Am J Psychiatry 163(8 Suppl), 5-82.
71. Veterans Administration/Department of Defense Evidence-Based Clinical Practice Guideline Working Group, Veterans Health Administration, Department of Veterans Affairs; and Health Affairs, Department of Defense (2001) Management of Substance Use Disorders in Primary and Specialty Care (Office of Quality and Performance Publication 10Q-CPG/SUD-01) Washington, DC: Department of Veterans Affairs
72. Institute of Medicine, Committee on Crossing the Quality Chasm (2006) Adaptation to Mental Health and Addictive Disorders: Improving the Quality of Health Care for Mental and Substance-Use Conditions Washington, DC: National Academies Press
73. F McCorry, D Garnick and J Bartlett (2000) Developing performance measures for alcohol and other drug services in managed care plans. Joint Commission J Quality Improvement 26 633-643.
74. American Society of Addiction Medicine (2001) ASAM Patient Placement Criteria for the Treatment of Substance Abuse Disorders 2nd ed, rev. Chevy Chase, MD: American Society of Addiction Medicine
75. MF Mayo-Smith (1997) Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 278 144-151.
76. MF Mayo-Smith, LH Beecher, TL Fischer, et al. (2004) Management of alcohol withdrawal delirium: an evidence-based practice guideline. Arch Intern Med 164 1405-1412.
77. National Institute on Alcohol Abuse and Alcoholism (2005) Helping Patients Who Drink Too Much: A Clinician's Guide (NIH Publication 05–3769) Bethesda, MD: National Institutes of Health
78. A Canagasaby and D Vinson (2005) Screening for hazardous or harmful drinking using one or two quantity-frequency questions. Alcohol Alcohol 40 208-213.
79. DF Reinert and JP Allen (2002) The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res 26 272-279.
80. DA Dawson, BF Grant, FS Stinson, et al. (2005) Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res 29 844-854.
81. JC Anthony, LA Warner and RC Kessler (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2 244-268.
82. RM Morse and DK Flavin (1992) The definition of alcoholism. JAMA 268 1012-1014.
83. JO Prochaska and CC DiClemente (1986) Towards a comprehensive model of change. WR Miller, N Heather (Eds) Treating Addictive Behaviors: Processes of Change New York: Plenum Press 3-27.
84. F Vocci and W Ling (2005) Medications development: successes and challenges. Pharmacol Ther 108 94-108.
85. CD Spies and H Rommelspacher (1999) Alcohol withdrawal in the surgical patient: prevention and treatment. Anesth Analg 88 946-954.
86. JC Garbutt, SL West, TS Carey, et al. (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281 1318-1325.
87. R Fuller, H Roth and S Long (1983) Compliance with disulfiram treatment of alcoholism. J Chronic Dis 36 161-170.
88. RK Fuller, L Branchey, DR Brightwell, et al. (1986) Disulfiram treatment of alcoholism. A Veterans Administration Cooperative Study. JAMA 256 1449-1455.
89. RK Fuller and HP Roth (1979) Disulfiram for the treatment of alcoholism: an evaluation in 128 men. Ann Intern Med 90 901-904.
90. RF Anton, DH Moak, PK Latham, et al. (2001) Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21 72-77.
91. JR Volpicelli, KC Rhines, JS Rhines, et al. (1997) Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54 737-742.
92. JH Krystal, JA Cramer, WF Krol, et al. (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 1734-1739.
93. RF Anton, SS O'Malley, DA Ciraulo, et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 295 2003-2017.
94. BJ Mason (2003) Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 13 469-475.
95. BJ Mason, AM Goodman, S Chabac and P Lehert (2006) Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 40 383-393.
96. BA Johnson, SS O'Malley, DA Ciraulo, et al. (2003) Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 23 281-293.
97. D Hall-Flavin, V Karpyak, M Vander Weg, et al. (2006) The use of acamprosate in a clinical population: initial Mayo Clinic experience. Alcohol Clin Exp Res 30 106A.
98. M Vander Weg, V Karpyak, D Hall-Flavin, et al. (2006) Comparability of the Penn Alcohol Craving Scale and the Obsessive Compulsive Drinking Scale for assessing craving in a clinical sample. Alcohol Clin Exp Res 30 161A.
99. O'Malley S. Public Communication. Presented at the International Society of Addiction Medicine Annual Meeting, Porto, Portugal, September 29, 2006.
100. VP Dole, ME Nyswander and MJ Kreek (1966) Narcotic blockade. Arch Intern Med 118 304-309.
101. RG Newman and WB Whitehill (1979) Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 2 485-488.
102. EC Strain, GE Bigelow, IA Liebson and ML Stitzer (1999) Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281 1000-1005.
103. G Bertschy (1995) Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci 245 114-124.
104. W Ling, C Charuvastra, SC Kaim and CJ Klett (1976) Methadyl acetate and methadone as maintenance treatments for heroin addicts. A Veterans Administration Cooperative Study. Arch Gen Psychiatry 33 709-720.
105. W Ling, CJ Klett and RD Gillis (1978) A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen. Arch Gen Psychiatry 35 345-353.
106. T Eissenberg, GE Bigelow, EC Strain, et al. (1997) Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. JAMA 277 1945-1951.
107. RE Johnson, MA Chutuape, EC Strain, et al. (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343 1290-1297.
108. W Ling, L Amass, S Shoptaw, et al. (2005) A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 1090-1100.
109. J Seifert, C Metzner, W Paetzold, et al. (2005) Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addict Biol 10 157-164.
110. DA Fiellin, MV Pantalon, MC Chawarski, et al. (2006) Counseling plus buprenorphine- naloxone maintenance therapy for opioid dependence. N Engl J Med 355 365-374.
111. RD Hurt, LC Dale, PA Fredrickson, et al. (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: one-year outcome and percentage of nicotine replacement. JAMA 271 595-600.
112. C Silagy, T Lancaster, L Stead, et al. (2002) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (4), CD000146.
113. C Silagy, T Lancaster, L Stead, et al. (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (3), CD000146.
114. RD Hurt, DP Sachs, ED Glover, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 1195-1202.
115. L Ferry and JA Johnston (2003) Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract 57 224-230.
116. C Oncken, D Gonzales, M Nides, et al. (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166 1571-1577.
117. M Nides, C Oncken, D Gonzales, et al. (2006) Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 1561-1568.
118. G Miller (2008) Psychopharmacology. Tackling alcoholism with drugs. Science 320 168-170.
119. BA Johnson, GM Campling, P Griffiths and PJ Cowen (1993) Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology (Berl) 112 142-144.
120. HR Kranzler, A Pierucci-Lagha, R Feinn and C Hernandez-Avila (2003) Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27 1150-1155.
121. J Cott, A Carlsson, J Engel and M Lindqvist (1976) Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol 295 203-209.
122. G Addolorato, F Caputo, E Capristo, et al. (2000) Ability of baclofen in reducing alcohol craving and intake: II—Preliminary clinical evidence. Alcohol Clin Exp Res 24 67-71.
123. G Colombo, R Agabio, MA Carai, et al. (2000) Ability of baclofen in reducing alcohol intake and withdrawal severity: I—Preclinical evidence. Alcohol Clin Exp Res 24 58-66.
124. G Colombo, S Serra, G Brunetti, et al. (2002) The GABA B receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol 37 499-503.
125. G Colombo, G Vacca, S Serra, et al. (2003) Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl) 167 221-224.
126. MS Cousins, DC Roberts and H de Wit (2002) GABA B receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 65 209-220.
127. Z Li, M Maglione, W Tu, et al. (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142 532-546.
128. HS White, SD Brown, JH Woodhead, et al. (1997) Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28 167-179.
129. DS Gryder and MA Rogawski (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23 7069-7074.
130. BA Johnson, N Ait-Daoud, CL Bowden, et al. (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361 1677-1685.
131. BA Johnson, N Ait-Daoud, FZ Akhtar and JZ Ma (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61 905-912.
132. BA Johnson, N Ait-Daoud, FZ Akhtar and MA Javors (2005) Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 165 1600-1605.
133. MA Frye, LL Altshuler, SL McElroy, et al. (2003) Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 160 883-889.
134. DT George, J Gilman, J Hersh, et al. (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319 1536-1539.
135. LS Covey and AH Glassman (1991) A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 86 991-998.
136. R Nemeth-Coslett, JE Henningfield, MK O'Keeffe and RR Griffiths (1986) Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl) 88 420-425.
137. P Pentel and D Malin (2002) A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 69 193-197.
138. SH de Villiers, N Lindblom, G Kalayanov, et al. (2002) Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 69 247-253.
139. FJ Vocci and CN Chiang (2001) Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs 15 505-514.
140. WD Hall (2005) Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med 2 e266. quiz e351.
141. A Oliveto, TR Kosten, R Schottenfeld, et al. (1995) Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J Subst Abuse Treat 12 423-428.
142. T Kosten, M Sofuoglu, J Poling, et al. (2005) Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict 14 8-17.
143. JG Gilbert, AH Newman, EL Gardner, et al. (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57 17-28.
144. MA Huestis, DA Gorelick, SJ Heishman, et al. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58 322-328.
145. RF Anton, G Oroszi, S O'Malley, et al. (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65 135-144.